Last update 21 Nov 2024

Ustekinumab-Aauz

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Ustekinumab Biosimilar (Fresenius Kabi USA, Inc.), 乌司奴单抗生物类似药(Fresenius Kabi USA, Inc.)
+ [4]
Mechanism
IL-12 inhibitors(Interleukin-12 inhibitors), IL-23 inhibitors(Interleukin-23 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Crohn's disease, active moderate
EU
25 Sep 2024
Crohn's disease, active moderate
LI
25 Sep 2024
Crohn's disease, active moderate
NO
25 Sep 2024
Crohn's disease, active moderate
IS
25 Sep 2024
Crohn's disease, active moderate
LI
25 Sep 2024
Crohn's disease, active moderate
NO
25 Sep 2024
Crohn's disease, active moderate
IS
25 Sep 2024
Crohn's disease, active moderate
EU
25 Sep 2024
Crohn's disease, active severe
LI
25 Sep 2024
Crohn's disease, active severe
NO
25 Sep 2024
Crohn's disease, active severe
EU
25 Sep 2024
Crohn's disease, active severe
EU
25 Sep 2024
Crohn's disease, active severe
NO
25 Sep 2024
Crohn's disease, active severe
IS
25 Sep 2024
Crohn's disease, active severe
LI
25 Sep 2024
Crohn's disease, active severe
IS
25 Sep 2024
Ulcerative colitis, active severe
NO
25 Sep 2024
Ulcerative colitis, active severe
IS
25 Sep 2024
Ulcerative colitis, active severe
LI
25 Sep 2024
Ulcerative colitis, active severe
EU
25 Sep 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Arthritis, PsoriaticNDA/BLA
US
30 Nov 2023
Plaque psoriasisNDA/BLA
US
30 Nov 2023
Immune System DiseasesPhase 1--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Pubmed
ManualManual
Not Applicable
-
491
(nmheydrnuf) = All 3 comparisons showed PK similarity, since the 90% confidence intervals of the respective geometric mean ratios for area under the concentration-time curve from time 0 to infinity and maximum serum concentration were contained within the acceptance interval of 80%-125%. orahfvenor (sxcuwtcijq )
Similar
19 Oct 2024
EU-Ref
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free